以周围灌注状态为目标与以血清乳酸水平为目标的复苏策略对脓毒性休克患者28天死亡率的影响:ANDROMEDA-SHOCK随机临床试验
该多中心随机试验在5个国家28个ICU纳入424例脓毒性休克患者,随机分为以毛细血管再充盈时间正常化为目标的逐步复苏方案(n=212)和以血清乳酸水平正常化或每2小时下降超过20%为目标的方案(n=212),干预8小时。主要终点28天全因死亡率在周围灌注组为34.9%,乳酸组为43.4%(HR 0.75,95%CI 0.55-1.02,P=0.06;风险差-8.5%,95%CI -18.2%至1.2%),未达统计学显著。周围灌注组72小时SOFA评分较低(5.6 vs 6.6,平均差-1.00,95%CI -1.97至-0.02,P=0.045)。其余6项次要终点无显著差异,未确认方案相关严重不良反应。
要点
- 脓毒性休克早期复苏以毛细血管再充盈时间正常化为目标,28天死亡率34.9%,以乳酸为目标的对照组43.4%,HR 0.75(95%CI 0.55-1.02),P=0.06,未达统计学显著。
- 周围灌注组72小时SOFA评分平均5.6,乳酸组6.6,平均差-1.00(95%CI -1.97至-0.02),P=0.045,提示周围灌注靶向复苏与较少器官功能障碍相关。
- 其余6项次要终点(90天死亡、无机械通气天数、无肾脏替代治疗天数、无血管加压药天数、ICU住院时间、医院住院时间)两组无显著差异。
- 未确认方案相关严重不良反应。
- 该研究为多中心随机试验,纳入424例成人脓毒性休克患者,干预8小时,随访至90天。
适用人群与场景
- 5个国家28个ICU纳入的成人脓毒性休克患者,共424例,平均年龄63岁,53%为女性。
- 纳入时间为2017年3月至2018年3月,末次随访日期为2018年6月12日。
处置流程与药物剂量
- 干预组(n=212):采用逐步复苏方案,目标为毛细血管再充盈时间正常化,干预8小时。
- 对照组(n=212):采用逐步复苏方案,目标为血清乳酸水平正常化或每2小时下降超过20%,干预8小时。
研究设计与关键结果
- 多中心随机试验,28个ICU,5个国家,纳入424例脓毒性休克患者,随机分为周围灌注靶向组(n=212)和乳酸靶向组(n=212),416例(98%)完成试验。
- 主要终点28天全因死亡率:周围灌注组74例(34.9%),乳酸组92例(43.4%),HR 0.75(95%CI 0.55-1.02),P=0.06;风险差-8.5%(95%CI -18.2%至1.2%)。
- 72小时器官功能障碍(SOFA评分,范围0最佳至24最差):周围灌注组平均5.6(SD 4.3),乳酸组6.6(SD 4.7),平均差-1.00(95%CI -1.97至-0.02),P=0.045。
- 其余6项次要终点(90天内死亡、28天内无机械通气天数、无肾脏替代治疗天数、无血管加压药天数、ICU住院时间、医院住院时间)无显著差异。
- 未确认方案相关严重不良反应。
证据类型、等级与局限
- 证据类型:多中心随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在脓毒性休克早期复苏中,以毛细血管再充盈时间正常化为目标的策略与以血清乳酸水平为目标的策略相比,28天全因死亡率无显著差异(34.9% vs 43.4%,P=0.06)。
- 周围灌注靶向复苏与72小时SOFA评分较低相关(平均差-1.00,95%CI -1.97至-0.02),但其余6项次要终点无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Abnormal peripheral perfusion after septic shock resuscitation has been associated with organ dysfunction and mortality. The potential role of the clinical assessment of peripheral perfusion as a target during resuscitation in early septic shock has not been established.
OBJECTIVE: To determine if a peripheral perfusion-targeted resuscitation during early septic shock in adults is more effective than a lactate level-targeted resuscitation for reducing mortality.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized trial conducted at 28 intensive care units in 5 countries. Four-hundred twenty-four patients with septic shock were included between March 2017 and March 2018. The last date of follow-up was June 12, 2018.
INTERVENTIONS: Patients were randomized to a step-by-step resuscitation protocol aimed at either normalizing capillary refill time (n = 212) or normalizing or decreasing lactate levels at rates greater than 20% per 2 hours (n = 212), during an 8-hour intervention period.
MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality at 28 days. Secondary outcomes were organ dysfunction at 72 hours after randomization, as assessed by Sequential Organ Failure Assessment (SOFA) score (range, 0 [best] to 24 [worst]); death within 90 days; mechanical ventilation-, renal replacement therapy-, and vasopressor-free days within 28 days; intensive care unit and hospital length of stay.
RESULTS: Among 424 patients randomized (mean age, 63 years; 226 [53%] women), 416 (98%) completed the trial. By day 28, 74 patients (34.9%) in the peripheral perfusion group and 92 patients (43.4%) in the lactate group had died (hazard ratio, 0.75 [95% CI, 0.55 to 1.02]; P = .06; risk difference, -8.5% [95% CI, -18.2% to 1.2%]). Peripheral perfusion-targeted resuscitation was associated with less organ dysfunction at 72 hours (mean SOFA score, 5.6 [SD, 4.3] vs 6.6 [SD, 4.7]; mean difference, -1.00 [95% CI, -1.97 to -0.02]; P = .045). There were no significant differences in the other 6 secondary outcomes. No protocol-related serious adverse reactions were confirmed.
CONCLUSIONS AND RELEVANCE: Among patients with septic shock, a resuscitation strategy targeting normalization of capillary refill time, compared with a strategy targeting serum lactate levels, did not reduce all-cause 28-day mortality.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03078712.
参考来源
- Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. JAMA. 2019. PMID: 30772908. doi:10.1001/jama.2019.0071
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。